nNOS


Also found in: Medical.
AcronymDefinition
nNOSNeuronal Nitric Oxide Synthase
NNOSNeonatal Neurological Optimality Score
References in periodicals archive ?
After washing twice (5 minutes) in PBS, the sections were incubated for 12 to 14 hours with purified rabbit antibodies for AQP2-3 (Chemicon, Temecula, CA; 1:2000, 1:1000, 1:1000, respectively) and monoclonal rabbit antibodies against eNOS and nNOS (Santa Cruz, CA; 1:1000 and 1:1000, respectively) in PBS with 0.
Dystrophin not only helps build muscle cells, it's also a key factor to attracting nNOS to the muscles cells and helping nNOS bind to the cell and help repair it following activity," Yi Lai, lead author of the study, said.
HSP90 has been implicated in interactions with both eNOS and nNOS that have regulatory significance.
Noronai NOS (nNOS) ve endoteliyal NOS (eNOS) izoformiarinin ekspresyonlarinin KOAH'li hastalar ye kontrol grubu arasinda farkli olmadigi ancak KOAH'li hastalarda nNOS ekspresyonunun havayolu obstruksiyonunun derecesi lie GSH-Px, SOD, MDA ve NO ile havayolu obstruksiyonu siddeti arasinda anlamli bulunmamis (23).
The synthetic analogues of L-arginine that are known to decrease NO concentration by inhibiting nNOS and eNOS are N-nitro-L-arginine methyl ester (L-NAME) and N-nitro-L-arginine (L-NA), N-monomethyl-L-arginine (L-NMMA) (1), and the nitro-indazole compound, 7-nitroindazole (7-NI) (16) are known to inhibit NO synthesis in the brain.
To further understand these properties of nNOS on its active site structural level, we have examined the oxygenase (heme-containing) domain of the two mutants in close comparison with that of wild-type nNOS with UV-visible absorption, magnetic circular dichroism (MCD), and electron paramagnetic resonance (EPR) spectroscopy.
36) The nNOS deficient mice initiated three to four times as many aggressive encounters as normal mice, and displayed only one-tenth as much submissive behavior as normal mice.
There are a variety of acronyms, ranging from NNOS (Not on Our Street) and LULU (Locally Unwanted Land Uses) to the more inclusive NOPE (Not on Planet Earth).
Bloch will provide an overview of NeurAxon and its portfolio of internally generated, novel, proprietary pain therapeutics including NXN-188, an oral, first-in-class selective nNOS inhibitor and 5HT agonist and NXN-462, an oral selective nNOS inhibitor.
Hopefully that will emerge with the NNOs and HWNZ working together to develop the systems and funding solutions to address this complex issue.